JC03 Rec'd PCT/PTO 06 OCT 2003

PTO-1390 (Rev. 2-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A SUBMISSION UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER
478.1072

U.S. APPLICATION (1) (I) KNOWN SEE 3 C.R.Z.5

INTERNATIONAL APPLICATION NO. PCT/GB2004/001627

INTERNATIONAL FILING DATE
14 April 2004 (14.04.2004)

PRIORITY DATE CLAIMED

14 April 2003 (14.04.2003)

TITLE OF INVENTION PHARMACEUTICAL COMPOSITIONS COMPRISING APOMORPHINE FOR PULMONARY INHALATION									
APPLICANT(S) FOR DO/EO/US Nicholas John STANIFORTH, David MORTON, Michael TOBYN, Stephen EASON, Quentin HARMER and David GANDERTON									
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:									
1.	\boxtimes	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.							
2.		This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.							
3.		This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.							
4.		The US has been elected (Article 31).							
5.	\boxtimes	A copy of the International Application as filed (35 U.S.C. 371(c)(2))							
		 a. is attached hereto (required only if not communicated by the International Bureau). b. is not required, as the application was filed in the United States Receiving Office (RO/US). 							
6.		An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).							
		 a. is attached hereto. b. has been previously submitted under 35 U.S.C. 154(d)(4). 							
7.	\boxtimes	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))							
		 a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 							
8.		An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).							
9.		An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).							
10.		An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).							
iter	ns 11 	to 20 below concern document(s) or information included:							
11.		An Information Disclosure Statement under 37 CFR 1.97 and 1.98.							
12.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.							
13.	\boxtimes	A preliminary amendment.							
14.	\boxtimes	An Application Datasheet under 37 CFR 1.76.							
15.	Ц	A substitute specification.							
16.		A power of attorney and/or change of address letter.							
17.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.							
18.		A second copy of the published international application under 35 U.S.C. 154(d)(4).							
19.		A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).							
20.	\boxtimes	Other items or information:							
		Letter re: Priority; International Search Report							

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark

JC09 Rec'd PCT/PTO 0 6 0CT 2009

PTO-1390 (Rev. 2-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICAT	Ng.(ktind	m.g. 2 c 3 R 1.5	0) INTERNATION PCT/O		PPLICATION 4/001627	NO.		Y'S DOCKET NO. 36,561			
		es have been submi					CALCULATIONS	PTO USE ONLY			
21.	Basic nationa	al fee			\$300	ŀ	\$ 300.00	<u> </u>			
22.	Examination	fee					·				
provisions of	of PCT Article	xamination report p e 333(1)-(4)	'	\$ 200.00							
Search fee (37	an Internation earch Report		\$ 400.00								
		OF 21, 22 and 23					\$				
sequence	fee for speci listing or con \$250 for each	ng									
Total Sheets	Extra Shee	ore I or	Number of each additional 50 or fraction thereof (round up to a whole number) RATE								
- 100 =	150	=			x \$250	=	\$				
Surcharge of \$ earliest claimed			\$								
CLAIMS	S N	NUMBER FILED	NUMBER EXTRA		RATE						
Total Claims		45 - 20 =	25	×	\$50		\$ 1250.00				
Independent C		1 - 3 =	0	х	\$200	=	\$ 0.00				
MULTIPLE DE	PENDENT C	\$0	<u> </u>								
			TOTAL OF ABOV			IS =	\$ 2150.00				
Applicant of by ½.	claims small e	\$									
		AL =	\$								
Processing fee the earliest clai		n +	\$								
TOTAL NATIONAL FEE =							\$ 2150.00				
Fee for recording accompanied by	ng the enclos by an appropr	+	\$								
-			TOTAL	L FEES	ENCLOSE	D =	\$ 2150.00				
							Amount to be refunded:	\$			
							Amount to be charged:	\$			
a. 🛭 A check	c in the amou	int of \$ <u>2150.00</u> to d	cover the above fees is	enclos	ed.						
	Please charge my Deposit Account No in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed.										
c. 🛭 The Co Deposit	mmissioner is Account No.	s hereby authorized . <u>50-05</u> 52. A duplic	to charge any addition	nal fees s enclo	which may sed.	be red	quired, or credit any o	verpayment to			
			WARNING: Informati Provide credit card info					ard information			
NOTE: Where	an appropri	iate time limit unde	er 37 CFR 1.494 or 1.4	95 has	not beep i			7 CFR 1.137(a) or			
(b)) must be filed and granted to restore the application to pending status. SEND ALL CORRESPONDENCE TO:											
Davidson, Davidson & Kappel, LLC SIGNATURE											
485 Seventh A	venue, 14th										
New York, NY 10018 Cary S. Kappel / NAME											
Dated: October 6, 2005 36,561											
Dateu. Octol			R								

10/552231 WEEKE NO 6 JCT 2005,

478.1072											
Jnit ned											
Invention: PHARMACEUTICAL COMPOSITIONS COMPRISING APOMORPHINE FOR PULMONARY INHALATION											
											
der 37											
450 on											
<u>-</u>											

478.1072

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Re:

Application of:

Nicholas John STANIFORTH, et al.

Serial No.:

To Be Assigned

Filed:

Herewith as national phase of International Application

No. PCT/GB2004/001627, filed April 14, 2004

For:

PHARMACEUTICAL COMPOSITIONS

COMPRISING APOMORPHINE FOR PULMONARY

INHALATION

LETTER RE: PRIORITY

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

October 6, 2005

Sir:

Applicant hereby claims priority from U.S. Patent Application Serial No. 10/413,022, filed April 14, 2004, and from U.S. Patent Application Serial No. 10/621,964, filed July 17, 2003, through PCT/GB2004/001627, filed April 14, 2004.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

By:

Cary S. Kappel Reg. No. 36,561

Davidson, Davidson & Kappel, LLC 485 Seventh Avenue, 14th Floor New York, New York 10018 (212) 736-1940